Trial Profile
Comparison of Pharmacodynamic Effects of Tirofiban vs. Cangrelor in N-STEMI Patients Undergoing Percutaneous Coronary Intervention
Status:
Discontinued
Phase of Trial:
Phase IV
Latest Information Update: 15 Dec 2023
Price :
$35
*
At a glance
- Drugs Cangrelor (Primary) ; Tirofiban (Primary)
- Indications Myocardial infarction
- Focus Pharmacodynamics
- 07 Dec 2023 Status changed from recruiting to discontinued.
- 09 Feb 2018 Planned End Date changed from 1 May 2018 to 29 May 2019.
- 09 Feb 2018 Planned primary completion date changed from 1 Apr 2018 to 1 Apr 2019.